Deciphera Pharmaceuticals Investor Presentation March 2023

Deciphera Pharmaceuticals presents its oncology pipeline and commercial strategy, featuring QINLOCK and clinical-stage candidates including vimseltinib and DCC-3116. The company outlines Phase 3 clinical trials, geographic expansion plans, and market opportunities across gastrointestinal stromal tumors and other cancer indications.